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ABSTRACT
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by 
widespread loss of lower motor neurons from the spinal cord, leading to progressive weakness and 
muscle atrophy. SMA is largely caused by homozygous loss of the survival motor neuron (SMN) 1 gene, 
resulting in reduced levels of full-length SMN protein. Although no approved treatment is currently 
available for SMA, several clinical trials investigating different approaches to increase SMN levels are 
showing promising early results. Trials investigating the use of therapies targeting muscle strength and 
neuroprotective pathways are also in progress, generating the possibility of delivering combination 
therapies utilising both SMN-dependent and SMN-independent targets. Due to an increased 
understanding of the cellular and molecular consequences of SMN depletion, a second wave of 
therapies targeted at pathways downstream of SMN are currently undergoing preclinical development. 
As these therapies move forward towards the clinic, new treatment options are likely to become 
available, raising the potential to generate an effective ‘cure’ for SMA.
Keywords: Spinal muscular atrophy (SMA), motor neuron, therapy, treatment, clinical trials.
INTRODUCTION
Spinal muscular atrophy (SMA) is a hereditary 
motor neuron disease characterised by loss of 
motor neurons from the anterior grey horn of the 
spinal cord.1 With an incidence of 1 in ~10,000 live 
births and a carrier frequency of 1 in ~35–50, this 
autosomal recessive disease is the most common 
genetic cause of infant mortality.2,3 In 95% of cases, 
SMA is caused by homozygous deletion of the 
survival motor neuron (SMN) 1 gene.4 In humans, 
there are two SMN genes, a telomeric SMN1 copy 
and an almost identical, centromeric SMN2 
copy.4 The SMN2 gene has a C to T substitution 
that results in the exclusion of exon 7 and the 
production of a truncated protein product, which 
is rapidly degraded.4,5 However, exclusion of 
exon 7 is incomplete, resulting in approximately 
10–15% of the protein produced from SMN2 being 
full-length SMN.6 As complete loss of SMN 
protein is embryonically lethal,7 SMA patients are 
dependent on SMN protein produced by the SMN2 
gene,8 with variability in protein levels occurring 
as a result of differences in SMN2 copy number; 
individuals with a higher SMN2 copy number have 
a less-severe disease phenotype.9 Thus, SMN2 copy 
number represents the primary determinant of 
disease severity in SMA.1 
The degeneration of lower motor neurons that 
occurs in SMA leads to a progressive decline in 
motor development, manifesting as muscle atrophy 
and weakness, primarily affecting proximal muscle 
groups.9 The profile of disease progression can vary 
substantially between patients with some phases 
of plateau in the decline of motor development.10 
Based on the age of onset, motor function 
achieved, and typical age of death, SMA can be 
classified into as many as five distinct clinical 
subgroups with varying severity.11 In all subtypes, 
molecular genetic analysis is now the gold 
standard for diagnosis.12 Type 0 onset occurs 
in utero with life not extending beyond the first 
few weeks after birth.1 Type 1 SMA, otherwise 
known as Werdnig–Hoffmann’s disease, is the 
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most common type of SMA.11 Disease onset occurs 
by 6 months and patients are unable to sit 
without support and cannot control head 
movement.2 Poor bulbar function and weak 
intercostal muscles lead to difficulties in feeding 
and breathing, resulting in death within the first 
2 years of life in the absence of palliative care.12 
Patients with Type 2 SMA (Dubowitz’s syndrome) 
have an intermediate phenotype, being able to 
maintain a sitting position unaided, but without 
the ability to walk independently.12 Onset occurs 
between 7 months and 18 months of age and 
death frequently occurs during adolescence 
due to respiratory problems.2 Type 3 SMA 
(Kugelbery–Welander’s disease) shows marked 
symptom heterogeneity; some patients are able 
to walk independently and have some muscular 
weakness, while others begin to walk but require 
wheelchair assistance in childhood.2 Type 4 SMA 
disease onset typically occurs in the second or 
third decade of life, with patients suffering from 
muscular weakness without respiratory problems.12 
For both SMA Type 3 and Type 4, life expectancy 
is often comparable to that of the general 
population.11 Several rare forms of SMA also exist, 
caused by mutations in genes other than SMN1. 
These include X-linked SMA, SMA with respiratory 
distress, and spinal and bulbar muscular atrophy 
(Kennedy’s disease).12
Following the identification of the disease-causing 
gene, it has become possible to model SMA in 
various animal systems.13,14 Studies in these animal 
models have led to an increased understanding 
of the molecular pathogenesis of SMA and have 
indicated that SMN replacement therapies may be 
a viable therapeutic strategy to treat SMA.1,2,12
THE SURVIVAL MOTOR 
NEURON PROTEIN 
In order to successfully target the SMN protein as 
a therapeutic approach for SMA, it is necessary 
to understand the functions of the SMN protein 
and the downstream effects of SMN reduction. SMN 
protein is a ubiquitously expressed, multifunctional 
protein that forms a macromolecular complex, 
essential for the splicing of pre-messenger 
RNAs (mRNAs).15-17 SMN associates with 
Gemins 2–8 and Unrip to form a complex that 
enables Sm core proteins and uridine-rich small 
nuclear ribonucleic acids to form small nuclear 
ribonucleoproteins (snRNPs).15,16 During pre-mRNA 
splicing, snRNPs are essential for the excision of 
introns from mRNA precursors in the nucleus.17 
Reduced SMN levels lead to a tissue-specific 
decrease in snRNP assembly that correlates with 
phenotypic severity in mouse models of SMA.18 
Moreover, widespread splicing defects have been 
found in SMA tissues with a wide diversity of 
genes being affected,19 including genes encoding 
splicing regulators and proteins required for 
motor circuit function.20,21 However, it has also 
been suggested that splicing defects may 
represent a late feature of SMA indicating that 
alternative splicing events could simply represent 
a consequence of disease progression in SMA, 
rather than the primary cause.22
Aside from its housekeeping function in snRNP 
assembly, SMN has been shown to have additional, 
non-canonical roles that may contribute to disease 
pathogenesis in SMA. During axonogenesis and 
axonal sprouting there is a progressive shift of 
SMN towards an axonal localisation in the human 
spinal cord, suggesting an axonal function of 
SMN.23 Indeed, SMN localises to axonal transport 
granules that deliver mRNAs to the synapse, 
where local translation can occur.24 SMN is also 
involved in axonal elongation, with loss of SMN 
leading to defects in axon outgrowth.14,25,26 Through 
interaction with mRNA binding proteins, SMN 
is involved in the localisation of beta-actin and 
beta-actin mRNA to growth cones of developing 
motor neurons, which leads to axonal elongation 
and growth cone size regulation.26 Interestingly, 
while SMN deficient motor neurons have 
reduced growth cone size,25,26 mice that lack 
beta-actin in motor neurons do not,27 indicating 
that other pathways contribute to the defective 
axonal elongation phenotype in SMA. Indeed, 
inappropriate activation of the Rho A/Rho-kinase 
(ROCK) pathway has been shown to lead to defects 
in neuritogenesis in SMA.28,29 Moreover, it has been 
demonstrated that insulin-like growth factor 1 
(IGF-1) is essential for enhancing axonal outgrowth 
of motor neurons. Intriguingly, circulating 
IGF-1 levels are also reduced as a consequence of 
the SMN reduction in SMA.30,31
Several other cellular and molecular pathways are 
also dysregulated in SMA due to reduced SMN 
levels. For example, ubiquitin homeostasis is 
altered in SMA whereby SMN depletion in mouse 
models of SMA leads to downregulation of 
ubiquitin-like modifier-activating enzyme 1 (UBA1) 
and accumulation of its downstream targets.32,33 
UBA1 activates ubiquitin as the first step of the 
ubiquitin conjugation process to mark proteins for 
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degradation by the proteasome.34 The proteasome 
has also been implicated in SMA pathogenesis 
as SMN degradation is mediated by the 
ubiquitin-proteasome system (UPS)35 and 
inhibiting proteasome function has been shown 
to increase SMN levels.36 Furthermore, the 
deubiquitinase Usp9x associates with and stabilises 
the SMN complex through interaction with SMN, 
which it deubiquitinates.5 Usp9x does not, however, 
deubiquitinate and stabilise the truncated SMN 
protein produced by SMN2, which is therefore 
rapidly degraded.33 The identification of these novel 
cellular and molecular functions of SMN opens up 
the possibility of developing SMN-independent 
therapies for the treatment of SMA.
SPINAL MUSCULAR ATROPHY AS A 
MULTISYSTEM DISORDER 
Regardless of whether therapies being developed 
are SMN-dependent or SMN-independent, one key 
element of any successful therapy is the ability 
to deliver it to cells, tissues, and organs affected 
by the disease. In the case of SMA, the main 
pathological target is undoubtedly alpha motor 
neurons;37 ~25–30% of motor neuron cell bodies 
are lost from the spinal cord of late symptomatic 
SMA mice.7 However, neuromuscular pathology is 
apparent before the overt loss of motor neuron cell 
bodies occurs in SMA.14,38 Thus, the neuromuscular 
system appears to develop relatively normally, but 
early on in the disease structural and functional 
defects are seen in both nerve and muscle.39,40 
These include early pathological changes at 
the neuromuscular junction (NMJ), including 
nerve terminal loss, synaptic accumulation of 
neurofilament proteins, and defective maturation 
of acetylcholine receptor clusters.39-41 Alongside 
these early changes in distal extremities of motor 
neurons, intrinsic defects have been reported in 
skeletal muscle, including smaller myotubes as 
well as reduced proliferation and fusion defects 
of myoblasts.42,43 These pathological changes 
in muscle occur independently of neuron 
degeneration and correlate with SMN reduction in 
model systems.38,42-44
Aside from lower motor neurons and skeletal 
muscle, low SMN levels also affect other cell types 
throughout the nervous system in SMA. For 
example, a defective myelination phenotype has 
been observed, resulting from intrinsic defects in 
Schwann cells in mouse models of SMA;45-47 altered 
function of astrocytes has also been implicated in 
SMA pathogenesis.48,49 Furthermore, pathological 
changes have been reported in the thalamus, 
cerebral cortex, brainstem, and dorsal root ganglia 
in severe cases of SMA.9 Alongside pathological 
changes in the nervous system and skeletal 
muscle, defects in peripheral tissues and organs 
including the heart, pancreas, blood vessels, and 
intestine have also been reported.8,9,50,51 One 
working hypothesis to explain the presence of 
extra-neuronal pathology in SMA is the ‘threshold 
hypothesis’ where differential thresholds for low 
SMN levels exist in different cell types, with motor 
neurons being most vulnerable in SMA due to their 
exceptional sensitivity to low levels of SMN.8,13
Although pathological extra-neural organ system 
phenotypes may often manifest at the subclinical 
level in SMA patients, they are becoming of 
increasing importance as therapies prolonging 
a patient’s survival run the risk of unmasking 
disorders of other organ systems. In addition, 
several recent studies have demonstrated that 
restoring SMN in motor neurons or skeletal muscle 
alone is insufficient to correct disease pathology 
in SMA mice, and that peripheral SMN restoration 
is likely to be essential for long-term rescue of 
SMA.30,52 Taken together, these findings suggest 
that any successful therapy for SMA will need to 
target not only motor neurons and skeletal muscle, 
but also more widespread, systemic pathology.
DEVELOPMENT OF NOVEL THERAPIES
FOR SPINAL MUSCULAR ATROPHY 
At present, no curative or disease-modifying 
therapies are available for patients with SMA. 
Palliative care options can assist with management 
of symptoms and prevention of complications. 
There are, however, several clinical trials aimed at 
modifying the disease that are currently underway 
in SMA patient cohorts. Given the central role that 
SMN plays in the disease, it is not surprising to 
find that the majority of clinical trials are aimed 
at increasing SMN protein levels. The current 
clinical trials can be split into four main groups, 
three based around a variety of approaches 
to increase SMN levels and one group of 
complementary therapies mainly comprising 
neuroprotective factors or muscle strength- 
enhancing compounds (Table 1). 
Gene therapy to replace the faulty SMN1 gene 
is one of the main technological approaches 
entering clinical trials, based on very promising 
preclinical data from animal models.80-83 
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Table 1: Current overview of clinical trials for spinal muscular atrophy as of June 2016.53-79
Trial number Study Status Type Sponsor
Gene therapy
NCT0212295255 Gene Transfer Clinical Trial for Spinal Muscular 
Atrophy Type 1
Ongoing 
- not 
recruiting
Phase I Jerry R. Mendell
Molecular therapy with ASO
NCT0238655356 A Study of Multiple Doses of ISIS SMNRx (ISIS 
396443) Delivered to Infants With Genetically 
Diagnosed and Presymptomatic Spinal Muscular 
Atrophy
Recruiting Phase II Biogen
NCT0246275957 A Study to Assess the Safety and Tolerabiity of ISIS 
396443 (ISIS SMNRx) in Participants With Spinal 
Muscular Atrophy (SMA)
Ongoing 
- not 
recruiting
Phase II Biogen
NCT0259412458 An Open-label Study (SHINE) for Patients With 
Spinal Muscular Atrophy (SMA) Who Participated 
in Studies With IONIS-SMNRx
Recruiting 
via 
invitation
Phase III Ionis 
Pharmaceuticals, 
Inc.
NCT0229253759 A Study to Assess the Efficacy and Safety of 
IONIS-SMN Rx in Patients With Later-onset Spinal 
Muscular Atrophy
Ongoing  
- not 
recruiting
Phase III Ionis 
Pharmaceuticals, 
Inc.
NCT0219307460 A Study to Assess the Efficacy and Safety of IONIS-
SMN Rx in Infants With Spinal Muscular Atrophy
Ongoing 
- not 
recruiting
Phase III Ionis 
Pharmaceuticals, 
Inc.
NCT0205279161 An Open-label Safety and Tolerability Study of Ionis 
SMNRx in Patients With Spinal Muscular Atrophy 
Who Previously Participated in IONIS SMNRx-C52 or 
IONIS SMNRx-CS10
Ongoing 
- not 
recruiting
Phase I Ionis 
Pharmaceuticals, 
Inc.
NCT0183965662 A Study to Assess the Safety and Pharmacokinetics 
of IONIS SMNRx in Infants With Spinal Muscular 
Atrophy
Ongoing 
- not 
recruiting
Phase II Ionis 
Pharmaceuticals, 
Inc.
NCT0178024663 An Open-label Safety and Tolerability Study of ISIS 
SMNRx in Patients With Spinal Mucular Atrophy 
Who Previously Participated in ISIS 396443-C51
Completed Phase I Ionis 
Pharmaceuticals, 
Inc.
NCT0170398864 An Open-label Safety, Tolerability and Dose-range 
Finding Study of Multiple Doses of ISIS SMNRx 
in Patients With Spinal Mucular Atrophy (SMNRx 
- C52)
Completed Phase I/II Ionis 
Pharmaceuticals, 
Inc.
NCT0149470165 An Open-label Safety, Tolerability and Dose-range 
Finding Study of ISIS SMNRx in Patients With 
Spinal Muscular Atrrophy
Completed Phase I Ionis 
Pharmaceuticals, 
Inc.
Small molecules enhancing SMN
NCT0226855266 An Open-label Study of LM1070 in Type 1 Spinal 
Muscular Atrophy (SMA)
Ongoing 
- not 
recruiting
Phase I/II Novaris 
Pharmaceuticals
NCT0224035567 A Study of RO6885247 in Adult and Pediatric 
Patients With Spinal Muscular Atrophy
Suspended Phase I Hoffman- 
La Roche
NCT0167138468 Valproate and Levocarnitine in Children With 
Spinal Muscular Atrophy
Recruiting Phase III All India Institute of 
Medical Sciences, 
New Delhi
NCT0066145369 CARNIVAL Type I: Valproic Acid and Carnitine in 
Infants With Spinal Mucular Atrophy (SMA) Type 1
Completed Phase I/II University of Utah
NCT0048101370 Valproic Acid in Ambulant Adults With Spinal 
Muscular Atrophy (VALIANTSMA)
Completed Phase II University of Utah
NCT0263370971 A Study to Investigate the Safety, Tolerability, 
Pharmacokinetics and Pharmacodynamics of 
RO7034067 (RG7916) Given by Mouth in Healthy 
Volunteers
Recruiting Phase I Hoffman-  
La Roche
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Several studies demonstrated that adeno- 
associated virus mediated SMN gene replacement 
resulted in widespread expression of SMN in 
the spinal cord and significantly increased 
survival of SMA model mice.80-83 In the ongoing 
Phase I gene therapy clinical trial, SMN within a 
self-complementary adeno-associated virus 
serotype 9 (scAAV9) vector is being delivered 
intravenously to Type 1 SMA patients (Table 1). 
As the use of gene therapy approaches are still 
not commonplace in the clinical setting, this initial 
clinical trial is evaluating both the safety and 
efficacy of the treatment in the small group of 
infants enrolled in the study (Table 1). 
A second therapeutic approach to increase SMN 
levels is to direct antisense oligonucleotides (ASOs) 
against sequences that inhibit the inclusion of 
SMN2 exon 7. The binding of ASOs to the regulatory 
motif prevents the binding of repressor factors. 
This promotes the inclusion of exon 7, thereby 
increasing the amount of full-length SMN produced 
by SMN2.84,85 The use of such ASOs in mouse 
models of SMA has shown promising results with 
survival prolonged by >100 days in some cases.86 
ASOs to treat SMA are currently in Phase II and 
Phase III of clinical trials (Table 1). Interestingly, 
trials using ASOs to treat other diseases, such as 
muscular dystrophy, are well advanced and have 
been instrumental in informing the study design 
and methodology used for ASOs trials in SMA.87 
The third SMN-targeted therapeutic approach 
entering clinical trials for SMA is based around small 
molecules that modify SMN2 splicing and increase 
SMN levels, including the use of histone deacetylase 
inhibitors such as valproic acid.88 Studies taking 
this more traditional pharmacological approach 
are currently at different stages of the clinical trial 
process, again after promising results from screens 
in rodent and cell models of SMA (Table 1).89
Regardless of the technological approach used 
to increase SMN levels, the ‘therapeutic time-
window’ within which therapy must be delivered 
in order to have a maximal effect needs to be 
considered. Several studies have indicated that 
SMN is required at the early stages of development 
and that sufficient SMN levels are essential for 
NMJ maturation in the early post-natal period.88-92 
It has also been demonstrated that late stage 
SMN gene replacement using scAAV9 failed to 
ameliorate NMJ defects, while pre-symptomatic 
delivery of scAAV9-SMN resulted in near complete 
rescue of the SMA phenotype.93 Together, 
these studies indicate that treatment using 
SMN-enhancing therapies will need to occur before 
overt symptoms are apparent for a full 
restoration of the SMA phenotype.
Table 1 continued.
Trial number Study Status Type Sponsor
Complementary/other
NCT0264466872 A Study of CK-2127107 in Patients Wth Spinal 
Muscular Atrophy
Recruiting Phase II Cytokinetics
NCT0262874373 A Study to Evaluate Long Term Safety, Tolerability, 
and Effectiveness of Olesoxime in Patients With 
Spinal Muscular Atrophy
Recruiting Phase II Hoffmann-
La Roche
NCT0130260074 Safety and Efficacy of Olesoxime (TRO19622) in 
3-25 Years SMA Patients
Completed Phase II Trophos
NCT0222782375 Safety and Efficacy Study of Pyridostigmine on 
Patients With Spinal Muscular Atrophy  
Type 3 (EMOTAS)
Recruiting Phase II Centre Hospitalier 
Régional de la 
Citadelle
NCT0164578776 Short and Long Term Treatment With 4-AP in 
Ambulatory SMA Patients
Completed Phase  
II/III
Columbia University
NCT0053322177 Pilot Study of Growth Hormone to Treat SMA  
Type II and III
Completed Phase II University Hospital 
Freiburg
NCT0052826878 Study to Evaluate Sodium Phenylbutyrate in 
Pre-symptomatic Infants With Spinal Muscular 
Atrophy (STOPSMA)
Completed Phase I/II NICHD
NCT0032445479 Levetiracetum for Cramps, Spasticity and 
Neuroprotection in Motor Neuron Disease
Completed Phase II Duke University
SMA: Spinal muscular atrophy; SMN: survival motor neuron; ASO: antisense oligonucleotides.
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While the first-generation of SMN-dependent 
therapies progress through the clinical trial 
process there is a wave of second-generation 
SMN-independent therapies currently in preclinical 
and clinical development. The most clinically 
advanced of these are centred around administering 
neuroprotective factors, or enhancing muscle 
strength (Table 1). Olesoxime is one potential 
neuroprotective factor currently in Phase II clinical 
trials for Type 2 or 3 SMA patients. This treatment 
acts by binding to components of the mitochondrial 
permeability pore, through which it can exert 
neuroprotective effects.94 Several drugs in trials 
to improve muscle strength have previously been 
approved for other disorders involving weakness 
of the neuromuscular system, while others are 
more recent developments, including CK-2127107 
(Table 1). This is a skeletal muscle troponin 
activator currently in trials to treat neuromuscular 
dysfunction, muscular weakness, and muscle 
fatigue.95 IGF-1 has also been used to try and 
improve muscular symptoms in SMA patients. 
Intravenous administration of AAV1-IGF-1 increased 
tissue levels of SMN, ameliorated muscle atrophy, 
and increased survival in SMA model mice.31 
However, in SMA patient trials, IGF-1 failed to reduce 
muscle atrophy.96 It has recently been found that 
the IGF-1 receptor is increased in the spinal cord 
of SMA mice.97 Hence, the beneficial effects 
of increasing IGF-1 might be restricted by the 
overexpression of IGF-1 receptor.97 Indeed, the 
same group showed that reducing IGF-1 receptor 
expression protects motor neurons and improves 
motor behaviour in a mouse model of SMA.97
Following on from recent developments in our 
understanding of the cellular and molecular 
pathways dysregulated downstream of SMN 
reduction in SMA (as discussed earlier), therapeutic 
strategies that target these pathways are also 
being developed. For example, members of the 
ROCK pathway have become attractive therapeutic 
targets due to their known potential to modulate 
axon outgrowth and growth cone motility. 
Although targeting downstream effectors of ROCK 
did not rescue the SMA phenotype,28 inhibiting 
ROCK led to positive outcomes in mouse models 
of SMA.98,99 Both Fasudil and Y-27632 inhibit ROCK 
and lead to an increase in the survival of SMA mice 
and improved NMJ maturation and muscle fibre 
size.98,99 Although toxicity was associated with 
Fasudil at high doses and motor neuron cell death 
was not reduced, the increase in survival points 
towards the importance of targeting muscle in SMA 
treatment strategies.98,99
The UPS has also recently been highlighted as a 
potentially attractive therapeutic target for SMA. 
Initial indications came from studies showing a role 
for the UPS in SMN degradation and stabilisation. 
Indeed, it has been demonstrated that inhibiting the 
chymotrypsin-like activity of the 26S proteasome 
using bortezomib increases SMN levels in 
peripheral tissues of SMA mice.36 This resulted in 
improved motor function and increased survival. 
When SMA mice were treated with a combination 
therapy of bortezomib and trichostatin A, 
a histone deacetylase inhibitor that increases 
SMN protein levels, the improvements observed 
across all aspects of the SMA phenotype were 
greater than when mice were treated with only 
one treatment.36 This study therefore provides 
proof-of-principal that combination therapies 
increasing SMN gene transcription and reducing 
SMN protein degradation may represent a viable 
therapeutic approach for SMA. However, due to 
toxicity issues associated with using available 
proteasome inhibitors such as bortezomib, 
targeting E3 ligases responsible for the specific 
ubiquitination of SMN may be a more suitable 
therapeutic approach to stabilise SMN.34 E3 ligases 
are the enzymes responsible for conferring the 
specificity of the UPS, therefore targeting them 
would be predicted to lead to a reduction in the 
non-specific effects associated with targeting the 
proteasome.34 Indeed, mind bomb 1 was recently 
identified as an E3 ligase responsible for the 
ubiquitination of SMN.100 Interestingly, loss of the 
Caenorhabditis elegans orthologue of mind bomb 1 
ameliorated the neuromuscular defects seen due 
to SMN1 loss of function.100
Alongside evidence suggesting that targeting 
SMN protein stability via the UPS may be an 
attractive therapeutic approach for SMA, recent 
experiments have demonstrated that UBA1, a key 
E1 ubiquitin-activating enzyme required for UPS 
function, is a major downstream target of SMN 
whose levels are robustly depleted in SMA.32,33 
This SMN-induced reduction of UBA1 levels 
leads to disruption of UBA1-dependent targets, 
such as an accumulation of beta-catenin.33 
Experiments in SMA animal models targeting these 
UBA1-dependent pathways have demonstrated 
improvements in neuromuscular phenotype, 
suggesting that these pathways are amenable to 
therapeutic intervention.33
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FUTURE DEVELOPMENT AND 
CONCLUDING REMARKS 
At present, there are no curative therapies for 
patients with SMA; however, several clinical trials 
aimed at modifying the disease are underway 
in patient cohorts. The focus of many of these 
clinical trials is augmenting full-length SMN 
protein levels. However, there is a second wave of 
SMN-independent therapies in preclinical and 
clinical development that target cellular and 
molecular pathways dysregulated downstream of 
SMN reduction in SMA.
Several major issues and questions will need 
answering before we are able to design and deliver 
fully effective therapies. For example, debate is 
still ongoing regarding whether restoration of SMN 
levels will be more important in the central nervous 
system and/or in peripheral tissues to successfully 
treat SMA.30,52,101 As previously mentioned, several 
studies in rodent models of the disease have 
shown that SMN restoration in extra-neural tissues 
and organ systems will likely be necessary for 
amelioration of the systemic SMA phenotype.30,52 
Were this situation to be recapitulated in 
human SMA patients, it could have significant 
consequences for the success of current clinical 
trials, many of which aim to increase SMN levels 
using delivery methods targeting the central 
nervous system (Table 1).
One other major issue that remains to be fully 
resolved concerns the presence of a therapeutic 
time-window after which therapy delivery can 
only have a minimal effect. Several studies 
have indicated that for maximal benefit, 
SMN-replacement therapies will need to be 
delivered before the onset of overt symptoms.91,93 
It will therefore be essential to understand 
how the recent mouse work relates to the 
temporal development of SMA pathogenesis in 
human patients.
It is possible that combination therapies will have 
the greatest potential to ameliorate the SMA 
disease phenotype. Combining SMN enhancement 
therapies with muscle strength-enhancing drugs 
or neuroprotective factors may help to preserve 
and strengthen the connections between 
neurons and muscles. This approach may result in 
effective treatment of SMA symptoms beyond the 
therapeutic time-window in which SMN-dependent 
therapies alone will be effective. An alternative 
combinatorial therapeutic avenue is the possibility 
of combining therapies to enhance SMN gene 
transcription with treatments to reduce SMN 
degradation and stabilise the protein (see previous 
discussion). This approach has the benefit of a 
possible dose reduction of the SMN-enhancing 
agent, which may help to reduce toxicity and 
increase efficacy.36 While the future looks bright 
for the progress of emerging treatments for SMA, 
it is necessary to continue investing in research 
covering a range of therapeutic approaches 
in order to get the best chance of success for 
developing an effective cure for SMA.
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